June 8, 2017August 24, 2022
Keytruda Improves Survival in Advanced Melanoma Patients Compared to Yervoy, Phase 3 Trial Shows
News
Patients with unresectable or metastatic melanoma who were treated with Keytruda (pembrolizumab) in a pivotal clinical trial showed superior and sustained time ... Read more
June 6, 2017
New Evidence Presented on Accuracy of DecisionDx-Melanoma Prognosis Test
News
Castle Biosciences presented three abstracts on the validity of using its 31-Gene Expression Profile (GEP) Test for melanoma prognosis at the ... Read more
June 1, 2017June 2, 2017
Biothera to Present Detailed Design of Combo Therapy Study for Melanoma, Breast Cancer
News
Biothera Pharmaceuticals will present the detailed study design of the IMPRIME-1 clinical trial at the upcoming 2017 ASCO Annual Meeting June 2-6 in ... Read more
May 30, 2017
Researchers Provide New Insights into Melanoma Immune Resistance
News
A new study presents detailed information into the processes used by cancer cells to evade and resist the immune response. Researchers studied ... Read more
May 25, 2017May 25, 2017
New Clinical Trial Underway for Treatment of Advanced Melanoma
News
A new clinical trial is underway assessing the addition of the first-in-class AXL kinase inhibitor, BGB324, to standard of care treatment for patients with ... Read more
May 23, 2017May 23, 2017
Skin Cancer Awareness Month Brings Sun Safety to Schools
News
Educating people of all ages, particularly children, about the dangers of sun exposure is urgent to preventing the increased prevalence ... Read more
May 18, 2017
First Patient Enrolled in ONCOS-102, Keytruda Combo Trial for Advanced Melanoma
News
The first patient has been enrolled in Targovax‘s pilot clinical trial for advanced or unresectable melanoma patients whose cancer progressed after treatment ... Read more
May 16, 2017
ImmunoPulse IL-12 and Keytruda Combo Therapy to be Tested in Phase 2 Trial
News
The combination of ImmunoPulse IL-12 and the anti-PD-1 therapy Keytruda (pembrolizumab) soon will be tested in a Phase 2 trial for treatment ... Read more
May 11, 2017
Binimetinib Improves Progression-free Survival of Certain Melanoma Patients in Phase 3 Trial
News
Adding the small molecule MEK inhibitor binimetinib to the BRAF inhibitor encorafenib was safe and significantly prolonged the time to disease progression ... Read more
May 9, 2017May 9, 2017
Melanoma Scientist Among 6 in NYC Awarded Prestigious Research Prize
News
The Pershing Square Sohn Cancer Research Alliance has announced the six winners of the fourth edition of the annual Pershing ... Read more
May 4, 2017
Castle’s Gene Test Shows Accuracy in Predicting Recurrence, Spread of Head and Neck Melanoma
News
Castle Biosciences’ DecisionDx-Melanoma test can be used to accurately predict cancer recurrence and metastasis in patients with head and neck melanoma, ... Read more
April 25, 2017
IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group
News
Prima Biomed, an Australian biotechnology company developing immunotherapies for cancer and autoimmune diseases, announced it has received approval for the ... Read more

March 13, 2015March 13, 2015

Delcath Submits Findings of Phase 3 Trial In Top Peer-reviewed Journal

Melanoma, News

Delcath Systems, Inc. a specialty pharmaceutical and device company with a primary focus on developing treatments for primary and metastatic liver cancer recently announced the publication of their Phase 3 ... Read more

March 11, 2015March 12, 2015

TGF-β Signals Can Influence Melanoma Cells’ Vulnerability To Drugs

News

A recent study published in Cell and titled “The Harmonies Played By TGF-β in Stem Cell Biology,” assessed how cancer cells respond to transforming growth factor beta (TGF-β) signals. These discoveries can lead to new approaches ... Read more

March 11, 2015March 11, 2015

Radiation Combined With Immunotherapy May Provide Optimal Response For Metastatic Melanoma

Melanoma, News

A new treatment strategy combining radiation therapy and two immunotherapies that target the CTLA4 and PD-1 pathways was recently shown to induce an optimal response in patients with metastatic melanoma. ... Read more

March 10, 2015April 21, 2015

FTC to Pursue Charges Against Melanoma Detection Apps

Melanoma, News

The Federal Trade Commission (FTC) has opened a case to end fraudulent advertisement regarding mobile apps that are supposed to diagnose melanoma through detecting symptoms or pictures of moles. While two marketers, MelApp ... Read more

March 9, 2015March 9, 2015

FDA Accepts Supplemental Biologics License Application for Yervoy as Adjuvant Treatment for Stage 3 Melanoma Patients

Melanoma, News

Bristol-Myers Squibb recently announced that the U.S. Food and Drug Administration (FDA) accepted the filing and review of the supplemental Biologics License Application (sBLA) for Yervoy (ipilimumab), a medication for the ... Read more

March 6, 2015March 6, 2015

Researchers Discover Pathway Responsible for Taste Loss in Skin Cancer Patients Under Chemotherapy Treatment

News, Skin Cancer

Researchers at the University of Michigan have recently discovered the molecular pathway that explains why patients under chemotherapy treatment experience changes in taste. The study was published in the Journal ... Read more

March 5, 2015March 5, 2015

Oleocanthal in Olive Oil Pokes Holes in Cancer Cells

News, Skin Cancer

Working in a laboratory at Rutgers University, Drs. Paul Breslin, David Foster, and Onica LeGendre discovered how a chemical component of olive oil kills human cancer cells derived from skin ... Read more

March 4, 2015March 4, 2015

Pioneering Blood-Based Biomarker Strategy Allows Early Cancer Detection in Mice

Melanoma, News

Researchers at Stanford University School of Medicine in California have recently revealed a new strategy for cancer detection via the use of blood-based biomarkers. The study is entitled “Detecting cancers ... Read more

March 3, 2015March 3, 2015

CURE OM Encourages Ocular Melanoma Patients to Share Stories

Melanoma, News

The Melanoma Research Foundation‘s Community United for Research and Education of Ocular Melanoma (CURE OM) program recently commended Oliver Sacks, a patient with ocular melanoma (OM), for sharing his experiences with the disease in ... Read more

March 2, 2015March 2, 2015

MD Anderson Studies Melanoma Patients Resistant To Therapy

Melanoma, News

Researchers from The University of Texas MD Anderson Cancer Center may have found a way to accurately predict which patients will be more likely to respond to genomic-based follow-up therapies by interpreting unique ... Read more

February 26, 2015February 26, 2015

Melanoma’s Addiction To Glutamine Explains Cancer Growth

News

Researchers from the Sanford-Burnham Medical Research Institute discovered that without a source of glutamine (one of the amino acids forming proteins) melanoma cells stop proliferating and die. Melanoma cells crave glutamine since they can overuse this essential nutrient as an ... Read more

February 25, 2015February 25, 2015

Decreased RNA-Editing Promotes Melanoma Progression

Melanoma, News

A new study entitled “Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis” showed how lack of RNA-editing, a key cellular process whereby RNA nucleotides are modified, contributes to tumor ... Read more

Keytruda Improves Survival in Advanced Melanoma Patients Compared to Yervoy, Phase 3 Trial Shows

New Evidence Presented on Accuracy of DecisionDx-Melanoma Prognosis Test

Biothera to Present Detailed Design of Combo Therapy Study for Melanoma, Breast Cancer

Researchers Provide New Insights into Melanoma Immune Resistance

New Clinical Trial Underway for Treatment of Advanced Melanoma

Skin Cancer Awareness Month Brings Sun Safety to Schools

First Patient Enrolled in ONCOS-102, Keytruda Combo Trial for Advanced Melanoma

ImmunoPulse IL-12 and Keytruda Combo Therapy to be Tested in Phase 2 Trial

Binimetinib Improves Progression-free Survival of Certain Melanoma Patients in Phase 3 Trial

Melanoma Scientist Among 6 in NYC Awarded Prestigious Research Prize

Castle’s Gene Test Shows Accuracy in Predicting Recurrence, Spread of Head and Neck Melanoma

IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group